UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 21, 2003
------------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------------- ----------- --------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
ITEM 9. Regulation FD Disclosure
On October 21, 2003, Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) and BioPredictive, a French
diagnostics firm, announced an exclusive partnership that combines LabCorp's
expertise in infectious disease testing with BioPredictive's noninvasive,
predictive testing technology to quantitatively determine the amount of liver
fibrosis, and the rate of its progression, in hepatitis C (HCV) patients. HCV
FIBROSURE-Trademark- is expected to be broadly available in the U.S., only
through LabCorp, beginning in the first quarter of 2004.
Exhibits:
99.1 Press release of the Company dated October 21, 2003.
SIGNATURES
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By:/s/ BRADFORD T. SMITH
----------------------------------
Bradford T. Smith
Executive Vice President
and Secretary
Date: October 21, 2003